# Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

> **NCT06374602** · PHASE2 · RECRUITING · sponsor: **Saint Petersburg State University, Russia** · enrollment: 20 (estimated)

## Conditions studied

- Anaplastic Thyroid Cancer

## Interventions

- **DRUG:** Pembrolizumab + Lenvatinib

## Key facts

- **NCT ID:** NCT06374602
- **Lead sponsor:** Saint Petersburg State University, Russia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-25
- **Primary completion:** 2026-03-25
- **Final completion:** 2026-06-25
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06374602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06374602, "Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06374602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*